Document:

Exhibit 10.3

 

GUARANTY

 

This
Guaranty is dated as of October 27, 2020, and made by the undersigned, Michael Witherill, Aaron Klusman, and Rivulet Media, Inc.,
a Delaware corporation (together “Guarantors”), to and in favor of Lawrence M. Silver (“Lender”).

 

Rivulet
Films, Inc., a Delaware corporation (“Borrower”), has executed and delivered a Multiple Advance Promissory
Note of even date hereof in the principal amount of $1,000,000, or such lesser amount as may be outstanding from time to time
(the “Note”).

 

As
an inducement for Lender to make advances under the Note, and for other good and valuable consideration, the sufficiency of which
is hereby acknowledged, Guarantors, jointly and severally, hereby unconditionally and irrevocably guarantee to Lender, or Lender’s
successors and assigns, the payment and performance of all of Borrower’s obligations arising from or created under the Note.

 

This
Guaranty is an absolute, unconditional, and continuing guaranty of the Note and not merely of the collectability of Borrower’s
obligations thereunder. Guarantors acknowledge that they are and shall be deemed a primary obligor of Borrower’s obligations
under the Note. This Guaranty is not conditioned upon any requirement that Lender first attempt to collect from Borrower or enforce
the Note against Borrower.

 

Guarantors
waive notice of acceptance of this Guaranty, presentment, and notice of default and any other notices required or customarily
given under like circumstances. This Guaranty shall terminate automatically upon payment in full of the Note.

 

This
Guaranty is governed by, and construed and enforced in accordance with, the internal substantive laws of the State of Arizona
(without reference to choice of law principles). The Guarantors unconditionally waive any right they may have to a trial by jury
in respect of any legal action arising out of or relating to this Guaranty.

 

	 	GUARANTORS:

                                                                      

	 	/s/
    Michael
    Witherill 
	 	Michael
    Witherill
	 	

                                                                                 

                                                                                /s/ Aaron
    Klusman 

	 	Aaron
    Klusman
	 	 
	 	Rivulet
    Media, Inc.,
	 	a
    Delaware corporation
	 	 
	 	By: 	/s/
    Michael
    Witherill 
	 	 	Michael
    Witherill, President

    1CERTAIN CONFIDENTIAL INFORMATION (MARKED BY BRACKETS AS “[*confidential treatment requested*]”) HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED.
Exhibit 10.1
​
​
Amendment No. 17 to the License Agreement
​
​

This Amendment No. 17 ("Amendment No. 17"), effective as of August 1, 2020, ("Amendment Effective Date") to the License Agreement dated as of November 1, 1994, by and between S&P Dow Jones Indices, LLC ("S&P")  and Cboe Exchange, Inc. ("CBOE"), as previously amended by Amendment No. 1 effective January 15, 1995, Amendment No. 2 effective April 1, 1998, Amendment No. 3 effective July 28, 2000, Amendment No. 4 effective October 27, 2000, Amendment No. 5 effective March 1, 2003, Amended and Restated Amendment No. 6 effective February 24, 2009 (which implemented "Addendum No. 1"), Amended and Restated Amendment No. 7 effective February 24, 2009, Amendment No. 8 effective January 9, 2005, Amendment No. 10 effective June 19, 2009, Amendment No. 11 effective April 29, 2010, Amendment No. 12 effective March 8, 2013, Amendment No. 13 effective December 21, 2017, Amendment No. 14 effective  January 1, 2017, Amendment No. 15 effective January 15, 2019, and Amendment No. 16 effective April 1, 2020 (Amendment No. 9 effective April 23, 2007 having been terminated as of February 24, 2009), (the License Agreement, as so amended, the "Prior Agreement"). This Amendment No. 17 and the Prior Agreement shall hereafter be known as the "Agreement".
WHEREAS, Cboe and S&P desire to establish a reduced fee to be paid to S&P in connection with trading on Cboe’s Markets of Mini-VIX Contracts (as defined below). 
NOW THEREFORE, the parties agree as follows:
1.New paragraph (z) is added to Section 1 of Addendum No. 1 to the Prior Agreement, as follows:

(z)“Mini-VIX Contract” means a Category I Product or Category II Product based on the Cboe Volatility Index (a/k/a the “VIX Index”) that has a notional value that is less than [*confidential treatment requested*] percent ([*confidential treatment requested*]%) of the notional value of the corresponding standard size Product.
2.Exhibit C to Addendum No. 1 of the Prior Agreement is hereby deleted and replaced in its entirety with amended and restated Exhibit C, attached hereto.
3.Terms that are used in this Amendment No. 17 with reference to the Prior Agreement but not modified or otherwise redefined herein shall have the respective meanings set forth in the Prior Agreement.  Provisions of the Prior Agreement not expressly modified by this Amendment No. 17 will continue in effect. 

The terms and conditions of this Amendment No. 17 are acknowledged and agreed to:
	​

	​

	​

	​

	Cboe Exchange, Inc.
	S&P Dow Jones Indices, LLC 

	​

	Signature:
	/s/ John F. Deters                                
	Signature:
	/s/ Jamie Farmer

	Name:
	John F. Deters
	Name:
	Jamie Farmer

	Title:
	EVP, CSO
	Title:
	Chief Commercial Officer

	Date:
	August 1, 2020
	Date:
	September 21, 2020

​
​

​
​

CERTAIN CONFIDENTIAL INFORMATION (MARKED BY BRACKETS AS “[*confidential treatment requested*]”) HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED.
​

EXHIBIT C
(to Addendum No. 1)
FEES
​
​
1.Pursuant to Section 6(a) of this Addendum No. 1, CBOE shall pay fees to S&P computed as follows: 
​
(1)For Category I Products and Category II Products based on any BuyWrite Index or a Volatility Index, other than a Mini-VIX Contract, a fee of $[*confidential treatment requested*] per Contract
​
(2)For Category I Products and Category II Products based on any Variance Indicator, a fee of: $[*confidential treatment requested*] per Contract during calendar year 2013; $[*confidential treatment requested*] per Contract during calendar year 2014; $[*confidential treatment requested*] per Contract during calendar years 2015-2022; and $[*confidential treatment requested*] per Contract during the remaining term of this Agreement
​
(3)For Mini-VIX Contracts, a fee of $[*confidential treatment requested*] per Contract
​
(4)[*confidential treatment requested*] percent ([*confidential treatment requested*]%) of all revenues received by CBOE, excluding sales, value-added and similar taxes, in connection with the license from CBOE to Rampart pursuant to the arrangement described in Section 2(f).
​
Notwithstanding the foregoing or any other provision of this Agreement:
​
(A)During any Volatility Index Non-exclusive Period (x) CBOE shall not be obligated to pay any fees with respect to Contracts on the Volatility Index subject to the Volatility Index Non-exclusive Period until such time during the term of the Agreement, if ever, as the Volatility Index Non-exclusive Period is no longer in effect for such Volatility Index, and (y) CBOE shall have no obligation to make any payment to S&P determined in accordance with Addendum No. 3.  If CBOE is successful in causing the Volatility Index Non-exclusivity Period no longer to be in effect during the term of the Agreement, CBOE shall promptly pay S&P an amount equal to the fees that CBOE did not pay pursuant to the foregoing sentence, reduced by an amount (but not to less than zero) equal to the costs incurred by CBOE to cause the Volatility Index Non-exclusive Period no longer to be in effect.
​
(B)If another Market (as defined below) provides a market for the trading of any Category I or Category II Product based on any BuyWrite Index or Variance Indicator without having been granted a license to do so by S&P with the consent of CBOE, CBOE shall have no obligation to pay any per-contract fee with respect to such Product during the time that such other Market is providing such a market.
​
The term “Market” as used in the preceding sentence is used to mean any regulated exchange or contract market, automated quotation system, electronic communications network or other similar market system.  
​
2.Pursuant to Section 6(b) of this Addendum No. 1, S&P shall pay fees to CBOE computed as follows:
​
[*confidential treatment requested*] percent ([*confidential treatment requested*]%) of all revenues, excluding sales, value-added and similar taxes, received by S&P in connection with 

​

CERTAIN CONFIDENTIAL INFORMATION (MARKED BY BRACKETS AS “[*confidential treatment requested*]”) HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED.
​

licenses granted by S&P to third parties that issue, sell, sponsor, distribute, market and/or promote Products based on the Amendment No. 6 Indexes, as contemplated under Section 3.
​
The parties acknowledge and agree that the Fee Schedule set forth in this Exhibit C shall have effect from and after August 1, 2020.
​
The parties agree that the terms upon which License Fees are calculated pursuant to this Exhibit C shall be considered confidential information of each party for purposes of Subsection 11(b) of the License Agreement.

​
​Exhibit 10.9

 

September 1, 2020

 

Mr. Sean Bohen

VIA EMAIL

 

Re:       Offer of Employment

 

Dear Sean:

 

Olema Pharmaceuticals, Inc. (the “Company”)
is pleased to offer you employment as the Company’s Chief Executive Officer (“CEO”) on the terms and conditions
set forth in this letter agreement (the “Agreement”).

 

1.                 
Commencement of Employment. Your employment with the Company will start today, September 1, 2020 (the “Start
Date”).

 

2.                 
Duties. As CEO, you will report to the Company’s Board of Directors (the “Board”) and will
devote your commercially reasonable efforts and full business time, skill and attention to the performance of your duties. You
will also be expected to adhere to the general employment policies and practices of the Company that may be in effect from time
to time, except that when the terms of this Agreement conflict with the Company’s general employment policies or practices,
this Agreement will control. During the period in which you are employed as the Company’s CEO, you will serve as a member
of the Board, subject to the Company first obtaining any required Board and/or stockholder approval. Unless the Board provides
otherwise, upon your termination of employment as CEO for any reason, you will automatically and without further action immediately
be deemed to have resigned from the Board. The Company may change your position, duties, work location and compensation from time
to time in its discretion, subject to the terms and conditions set forth herein.

 

3.                 
Salary. You will be paid an annual base salary of $500,000, less applicable deductions and withholdings, to be
paid each month in accordance with the Company’s payroll practices, as may be in effect from time to time.

 

4.                 
Benefits. You will be eligible to participate in the Company’s standard benefit programs, subject to the
terms and conditions of such plans. The Company may, from time to time, change these benefits in its discretion. Additional information
regarding these benefits is available for your review upon request. The parties acknowledge and agree that you will be taking a
vacation to France for approximately 10 days in September 2020, with the exact dates to be determined between the parties.

 

5.                 
Stock Options. Subject to approval by the Board, at the first Board meeting following the Start Date which in
no event shall be later than September 15, 2020 (provided you have commenced employment by such date), the Company will grant you
an option to purchase that number of shares of the Company’s common stock equal to 5% of the Company’s total fully-diluted
shares (excluding unissued shares reserved for issuance under the Plan) as of the Start Date (the “Option”). The Option
shall vest over a four-year period, with one quarter of the shares subject to the Option vesting on the first anniversary of the
Start Date, and the remaining shares vesting equally over the following 36 months of continuous service; provided that upon the
closing of a Change in Control (as defined below), the vesting of the Option will be accelerated such that 100% of the shares subject
to the Option will be deemed fully vested and exercisable. The Option shall be issued pursuant to the terms and conditions of the
Company’s 2014 Stock Plan (the “Plan”), at an exercise price equal to 100% of the fair market value of the Company’s
common stock on the date of grant, as provided in the Plan and consistent with the requirements for an exemption from the application
of Section 409A of the Internal Revenue Code (the “Code”), and shall be governed in all respects by the terms of the
Plan, the grant notice (the form of which shall be in substantially the form attached as Exhibit A) and the option
agreement (the form of which shall be in substantially the form attached as Exhibit B).

 

    1

    Page 2

    

 

6.                 
Performance Bonuses. Each year, you will be eligible to earn an annual incentive bonus equal to 50% of your annual
base salary (prorated for 2020). Whether you receive a bonus, and the amount of any such bonus, shall be determined by the Board
in its reasonable discretion, and shall be based upon achievement of performance objectives to be mutually agreed upon between
you and the Board (or duly authorized committee thereof) and other criteria to be reasonably determined by the Board. Any annual
bonus shall be paid within 30 days after the Board’s determination that a bonus shall be awarded and in any event shall be
paid by March 15 for the immediately preceding year. You must be employed on the day that your bonus (if any) is paid in order
to earn the bonus. Therefore, if your employment is terminated either by you or the Company for any reason prior to the bonus being
paid, you will not have earned the bonus and no partial or prorated bonus will be paid. Notwithstanding the foregoing, if your
employment is terminated by the Company without Cause (as defined below), or you resign for Good Reason (as defined below), in
either case after the end of a calendar year, but before the bonus for that year has been paid, then you will remain eligible to
a bonus for that preceding year, to be awarded and paid on the same terms as the remaining executive team.

 

7.                 
Severance.

 

(a)              
Termination For Cause; Resignation Without Good Reason. If, at any time, the Company terminates your employment
for Cause (as defined herein), or if you resign without Good Reason (as defined herein), or if either party terminates your employment
as a result of your death or disability, you will receive your base salary accrued through your last day of employment, as well
as any unused vacation (if applicable) accrued through your last day of employment. Under these circumstances, you will not be
entitled to any other form of compensation from the Company, including severance benefits.

 

(b)             
Termination without Cause; Resignation for Good Reason. If, at any time, the Company terminates your employment
without Cause or you resign for Good Reason, and other than as a result of your death or disability, and provided such termination
constitutes a “separation from service” (as defined under Treasury Regulation Section 1.409A-1(h), without regard to
any alternative definition thereunder, a “Separation from Service”), then subject to your obligations below, you shall
be entitled to receive the following severance benefits (collectively, the “Severance Benefits”):

 

    

    Page 3

    

 

(i)                
an amount equal to one year of your then-current base salary, less all applicable withholdings and deductions, paid over
such one-year period, on the schedule described below (the “Salary Continuation”);

 

(ii)             
if you timely elect continued coverage under COBRA for yourself and your covered dependents under the Company’s group
health plans following such termination or resignation of employment, then the Company shall pay the COBRA premiums necessary to
continue your health insurance coverage in effect for yourself and your eligible dependents on the termination date until the earliest
of (A) the close of the one-year period following the termination of your employment, (B) the expiration of your eligibility for
the continuation coverage under COBRA, and (C) the date when you become eligible for substantially equivalent health insurance
coverage in connection with new employment or self-employment. If you become eligible for coverage under another employer's group
health plan or otherwise cease to be eligible for COBRA during the period provided in this clause, you must immediately notify
the Company of such event, and all payments and obligations under this clause shall cease;

 

(iii)           
acceleration of the vesting of the Option as of the date of termination as to the number of shares that would have vested
in accordance with the applicable vesting schedule as if you had been in service for an additional one-year period following your
termination date (based upon months of service and not the occurrence of corporate events or milestones); provided, however, that
if the Company terminates your employment without Cause or you resign for Good Reason, in either case within the period starting
three months prior to, or 12 months following, the effective date of a Change in Control (as defined below), then the vesting of
the Option will be accelerated such that 100% of the shares subject to the Option will be deemed fully vested and exercisable.

 

Such Severance Benefits are conditional
upon (a) your continuing to comply with your obligations under your Employee Proprietary Information and Invention Assignment Agreement;
(b) your delivering to the Company an effective, general release of claims in favor of the Company in substantially the form attached
as Exhibit C within 60 days following your termination date; and (c) if you are then a member of the Board, your
resignation from the Board, to be effective no later than the date of your termination date (or such other date as requested by
the Board). The Salary Continuation will be paid in equal installments on the Company’s regular payroll schedule and will
be subject to applicable tax withholdings over the period outlined above following the date of your termination date; provided,
however, that no payments will be made prior to the 60th day following your Separation from Service. On the 60th day following
your Separation from Service, the Company will pay you in a lump sum the Salary Continuation and other Severance Benefits that
you would have received on or prior to such date under the original schedule but for the delay while waiting for the 60th day in
compliance with Code Section 409A and the effectiveness of the release, with the balance of the Salary Continuation and other Severance
Benefits being paid as originally scheduled.

 

8.                 
Definitions.

 

(a)              
Cause. For purposes of this Agreement, “Cause” means any of the following: (i) theft, breach of fiduciary
duty, or falsification of Company documents or records; (ii) material failure to abide by any Company policy after written notice
from the Company regarding failure to abide by such policy; (iii) intentional and unauthorized use, misappropriation, destruction
or diversion of any material tangible or intangible asset or corporate opportunity of the Company (including, without limitation,
improper use or disclosure of the Company’s confidential or proprietary information); (iv) any intentional act that has a
material detrimental effect on the Company’s reputation or business; (v) repeated failure or inability to perform any reasonable
assigned duties after written notice from the Company of, and a reasonable opportunity to cure, such failure or inability; (vi)
any material breach of any contractual or legal obligation to the Company and the failure to cure within ten (10) days after delivery
of written notice thereof (to the extent such breach or violation is curable); or (vii) conviction (including any plea of guilty
or nolo contendere) of any felony.

 

    

    Page 4

    

 

(b)             
Good Reason. For purposes of this Agreement, “Good Reason” shall mean that you have resigned based
on the occurrence of any of the following events: (i) a material diminution in your base salary except for across-the-board salary
reductions similarly affecting all or substantially all senior executives of the Company; (ii) a change in the geographic location
of your primary place of work that results in an increase in your one-way commute by more than 25 miles (provided, however,
that this subclause (ii) shall only be applicable after the Company resumes normal in-person office operations in connection with
the COVID-19 pandemic); (iii) a material reduction in your job duties or responsibilities (not simply a change in title or reporting
relationships); or (iv) a material breach of this Agreement by the Company; provided, however, that you shall not
be deemed to have Good Reason if the Company survives as a separate legal entity following a Change in Control and you hold materially
the same position in such legal entity as before the Change in Control. A resignation will only be for Good Reason if you deliver
written notice of such condition to the Company within 30 days after the initial occurrence of such condition, the Company has
failed to cure such condition within 30 days after the delivery of such notice, and you in fact resign within 45 days after the
initial notice.

 

(c)              
Change in Control. For purposes of this Agreement, “Change in Control” means (i) a sale of all or
substantially all of the Company’s assets other than to an Excluded Entity (as defined below); (ii) a merger, consolidation
or other capital reorganization or business combination transaction of the Company with or into another corporation, limited liability
company or other entity other than an Excluded Entity; or (iii) the consummation of a transaction, or series of related transactions,
in which any “person” (as such term is used in Sections 13(d) and 14(d) of the Securities Exchange Act of 1934, as
amended) becomes the “beneficial owner” (as defined in Rule 13d-3 of the Securities Exchange Act of 1934, as amended),
directly or indirectly, of all of the Company’s then outstanding voting securities. An “Excluded Entity” means
a corporation or other entity of which the holders of voting capital stock of the Company outstanding immediately prior to such
transaction are the direct or indirect holders of voting securities representing a majority of the votes entitled to be cast by
all of such corporation’s or other entity’s voting securities outstanding immediately after such transaction.

 

9.                 
Section 409A. The payments and benefits under this Agreement are intended to qualify for exemptions from the
application of Section 409A of the Internal Revenue Code (“Section 409A”), and this Agreement will be construed to
the greatest extent possible as consistent with those provisions, and to the extent not so exempt, this Agreement (and any definitions
hereunder) will be construed in a manner that complies with Section 409A to the extent necessary to avoid adverse taxation under
Section 409A. Notwithstanding anything to the contrary herein, to the extent required to comply with Section 409A, a termination
of employment shall not be deemed to have occurred for purposes of any provision of this Agreement providing for the payment of
amounts or benefits upon or following a termination of employment unless such termination is also a Separation from Service. Your
right to receive any installment payments will be treated as a right to receive a series of separate payments and, accordingly,
each installment payment shall at all times be considered a separate and distinct payment. Notwithstanding any provision to the
contrary in this Agreement, if you are deemed by the Company at the time of your Separation from Service to be a “specified
employee” for purposes of Section 409A, and if any of the payments upon Separation from Service set forth herein and/or under
any other agreement with the Company are deemed to be “deferred compensation,” then, to the extent delayed commencement
of any portion of such payments is required in order to avoid a prohibited distribution under Section 409A and the related adverse
taxation under Section 409A, such payments shall not be provided to you prior to the earliest of (a) the expiration of the six-month
period measured from the date of Separation from Service, (b) the date of your death or (c) such earlier date as permitted under
Section 409A without the imposition of adverse taxation. With respect to payments to be made upon execution of an effective release,
if the release revocation period spans two calendar years, payments will be made in the second of the two calendar years to the
extent necessary to avoid adverse taxation under Section 409A. With respect to reimbursements or in-kind benefits provided hereunder
(or otherwise) that are not exempt from Section 409A, the following rules shall apply: (x) the amount of expenses eligible for
reimbursement, or in-kind benefits provided, during any one taxable year shall not affect the expenses eligible for reimbursement,
or in-kind benefit to be provided in any other taxable year, (y) in the case of any reimbursements of eligible expenses, reimbursement
shall be made on or before the last day of the taxable year following the taxable year in which the expense was incurred and (z)
the right to reimbursement or in-kind benefits shall not be subject to liquidation or exchange for another benefit.

 

    

    Page 5

    

 

10.             
Confidentiality Obligations. As condition of your employment, you must sign and abide by the Company’s
standard form of Employee Proprietary Information and Invention Assignment Agreement, a copy of which is attached hereto as Exhibit
D.

 

11.             
At-Will Employment. Your employment with Company will be “at-will.” This means that either you or
Company may terminate your employment at any time, with or without Cause, and with or without advance notice.

 

12.             
Arbitration. To ensure the timely and economical resolution of disputes that may arise between you and the Company,
both you and the Company mutually agree that pursuant to the Federal Arbitration Act, 9 U.S.C. §1-16, and to the fullest extent
permitted by applicable law, you will submit solely to final, binding and confidential arbitration any and all disputes, claims,
or causes of action arising from or relating to: the negotiation, execution, interpretation, performance, breach or enforcement
of this Agreement; or your employment with the Company (including but not limited to all statutory claims); or the termination
of your employment with the Company (including but not limited to all statutory claims). BY AGREEING TO THIS ARBITRATION PROCEDURE,
BOTH YOU AND THE COMPANY WAIVE THE RIGHT TO RESOLVE ANY SUCH DISPUTES THROUGH A TRIAL BY JURY OR JUDGE OR THROUGH AN ADMINISTRATIVE
PROCEEDING. The Arbitrator shall have the sole and exclusive authority to determine whether a dispute, claim or cause of action
is subject to arbitration under this section and to determine any procedural questions which grow out of such disputes, claims
or causes of action and bear on their final disposition. All claims, disputes, or causes of action under this section, whether
by you or the Company, must be brought solely in an individual capacity, and shall not be brought as a plaintiff (or claimant)
or class member in any purported class or representative proceeding, nor joined or consolidated with the claims of any other person
or entity. The Arbitrator may not consolidate the claims of more than one person or entity, and may not preside over any form of
representative or class proceeding. To the extent that the preceding sentences in this paragraph are found to violate applicable
law or are otherwise found unenforceable, any claim(s) alleged or brought on behalf of a class shall proceed in a court of law
rather than by arbitration. Any arbitration proceeding under this Arbitration section shall be presided over by a single arbitrator
and conducted by JAMS, Inc. (“JAMS”) in San Francisco, CA under the then applicable JAMS rules for the resolution of
employment disputes (available upon request and also currently available at http://www.jamsadr.com/rules-employment-arbitration/).
You and the Company both have the right to be represented by legal counsel at any arbitration proceeding, at each party’s
own expense. The Arbitrator shall: (a) have the authority to compel adequate discovery for the resolution of the dispute; (b) issue
a written arbitration decision, to include the arbitrator’s essential findings and conclusions and a statement of the award;
and (c) be authorized to award any or all remedies that you or the Company would be entitled to seek in a court of law. The Company
shall pay all JAMS arbitration fees in excess of the amount of court fees that would be required of you if the dispute were decided
in a court of law. This section shall not apply to any action or claim that cannot be subject to mandatory arbitration as a matter
of law, including, without limitation, claims brought pursuant to the California Private Attorneys General Act of 2004, as amended,
the California Fair Employment and Housing Act, as amended, and the California Labor Code, as amended, to the extent such claims
are not permitted by applicable law to be submitted to mandatory arbitration and such applicable law is not preempted by the Federal
Arbitration Act or otherwise invalid (collectively, the “Excluded Claims”). In the event you intend to bring multiple
claims, including one of the Excluded Claims listed above, the Excluded Claims may be filed with a court, while any other claims
will remain subject to mandatory arbitration. Nothing in this section is intended to prevent either you or the Company from obtaining
injunctive relief in court to prevent irreparable harm pending the conclusion of any such arbitration. Any final award in any arbitration
proceeding hereunder may be entered as a judgment in the federal and state courts of any competent jurisdiction and enforced accordingly.

 

    

    Page 6

    

 

13.             
Miscellaneous. This Agreement is the complete and exclusive statement of all of the terms and conditions of your
employment with the Company, and supersedes and replaces any and all prior agreements or representations with regard to the subject
matter hereof, whether written or oral. It is entered into without reliance on any promise or representation other than those expressly
contained herein, and it cannot be modified, amended or extended except in a writing signed by you and a duly authorized member
of the Board. This Agreement is intended to bind and inure to the benefit of and be enforceable by you and the Company, and our
respective successors, assigns, heirs, executors and administrators, except that you may not assign any of your duties or rights
hereunder without the express written consent of the Company. Whenever possible, each provision of this Agreement will be interpreted
in such manner as to be effective and valid under applicable law, but if any provision of this Agreement is held to be invalid,
illegal or unenforceable in any respect under any applicable law or rule in any jurisdiction, such invalidity, illegality or unenforceability
will not affect any other provision or any other jurisdiction, but this Agreement will be reformed, construed and enforced as if
such invalid, illegal or unenforceable provisions had never been contained herein. This Agreement and the terms of your employment
with the Company shall be governed in all aspects by the laws of the State of California.

 

    

    Page 7

    

 

This offer is subject to satisfactory proof
of your right to work in the United States and satisfactory completion of a Company-required background check. If you agree to
the terms and conditions set forth herein, please sign below.

 

We look forward to having you join us.
If you have any questions about this Agreement, please do not hesitate to call me.

 

	Best regards,	 
	 	 
	/s/
    Ian Clark	 
	Ian Clark	 
	Chair of the Board	 
	 	 
	Accepted and agreed:	 
	 	 
	/s/
    Sean Bohen	 
	Sean Bohen	 
	 	 
	Date: 	9/1/2020

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00316-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00316-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00316-of-00352.parquet"}]]